12 completed. 12 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 12 | Completed 12 |
Follow Hyperphosphatemia: new trials by email Literature Review of Hyperphosphatemia trials Research Report on Hyperphosphatemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Cholestyramine in the Management of Hyperphosphatemia in Adult Hemodialysis Patients Cholestyramine Resin 4000 MG [Questran], Calcium Carbonate 500 MG Oral Tablet - Chronic Kidney Diseases, Hemodialysis Complication | Phase 4 | Completed | Ain Shams University | 80 | 2023-03-30 | 2024-08-06 |
| Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants Ferric Citrate 1 gram Oral Tablet, Standard of care phosphate-lowering therapy - Hyperphosphatemia, Anemia, Iron Deficiency | Phase 4 | Completed | USRC Kidney Research | 214 | 2021-06-29 | 2022-11-07 |
| Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia Tenapanor - Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia | Phase 4 | Completed | Ardelyx | 333 | 2020-11-20 | 2023-03-29 |
| Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients Sucroferric Oxyhydroxide Chewable Tablet - Peritoneal Dialysis Complication, Hyperphosphatemia | Phase 4 | Completed | University of Colorado, Denver | 17 | 2020-02-01 | 2022-08-31 |
| A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP Tenapanor, Sevelamer Carbonate - Hyperphosphatemia, End Stage Renal Disease | Phase 4 | Completed | Ardelyx | 172 | 2019-06-15 | 2023-03-29 |
| Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients Ferric Citrate - Hyperphosphatemia | Phase 4 | Completed | Kaiser Permanente | 55 | 2017-05-01 | 2022-01-13 |
| Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis Ferric Citrate - Kidney Failure, Chronic, End-stage Renal Disease | Phase 4 | Completed | Panion & BF Biotech Inc. | 202 | 2017-04-12 | 2020-01-13 |
| Phosphate Lowering in CKD Trial Lanthanum carbonate, placebo, Ascorbic Acid - Chronic Kidney Disease, Cardiovascular Disease | Phase 4 | Completed | VA Office of Research and Development | 66 | 2014-09-15 | 2022-08-26 |
| Phosphate Kinetic Modeling 2 PKM Algorithm - Hyperphosphatemia, ESRD | Phase 4 | Completed | Fresenius Medical Care North America | 81 | 2010-09-01 | 2014-08-18 |
| Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients Sevelamer HCl, Calcium-based phosphate binder - Hemodialysis, Hyperphosphatemia | Phase 4 | Completed | Chugai Pharma Taiwan | 166 | 2007-06-01 | 2014-08-05 |
| Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism paricalcitol - Secondary Hyperparathyroidism | Phase 4 | Completed | Papageorgiou General Hospital | 2005-02-01 | 2006-03-28 | |
| CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients calcium acetate, sevelamer, atorvastatin - Calcinosis, Arteriosclerosis | Phase 4 | Completed | Nabi Biopharmaceuticals | 203 | 2005-01-01 | 2008-01-08 |
Kidney Failure, Chronic (3) · Renal Insufficiency (3) · Renal Insufficiency, Chronic (3) · Hyperparathyroidism, Secondary (2) · Anemia, Iron-Deficiency (1) · Arteriosclerosis (1) · Calcinosis (1) · Cardiovascular Diseases (1) · Hypercalcemia (1) · Hypoalbuminemia (1) · Kidney Diseases (1) · Metabolic Diseases (1) · Phosphorus Metabolism Disorders (1) · Urologic Diseases (1)
Nutritional and Metabolic Diseases (12) · Metabolic Diseases (11) · Phosphorus Metabolism Disorders (11) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Male Urogenital Diseases (7) · Urogenital Diseases (7) · Kidney Diseases (6) · Urologic Diseases (6) · Chronic Disease (5) · Disease Attributes (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Renal Insufficiency (4) · Calcium Metabolism Disorders (2)
Sevelamer (3) · ferric citrate (3) · Calcium Carbonate (2) · calcium acetate (2) · tenapanor (2) · Ascorbic Acid (1) · Atorvastatin (1) · Cholestyramine Resin (1) · Nitroglycerin (1) · Tablets (1) · lanthanum carbonate (1) · paricalcitol (1)
Ardelyx (2) · Ain Shams University (1) · Chugai Pharma Taiwan (1) · Fresenius Medical Care North America (1) · Kaiser Permanente (1) · Nabi Biopharmaceuticals (1) · Panion & BF Biotech Inc. (1) · Papageorgiou General Hospital (1) · USRC Kidney Research (1) · University of Colorado, Denver (1) · VA Office of Research and Development (1)
United States (8) · Egypt (1) · Taiwan (1)
Anna J Jovanovich, MD (1) · Chiu-Ching Huang, Professor (1) · David P Rosenbaum, PhD (1) · Efstathios Mitsopoulos, MD (1) · Jessica Kendrick, MD (1) · Mai-Szu Wu, M.D. (1) · Peter Kotanko, MD (1) · Victoria Kumar, MD (1) · Wajeh Y Qunibi, M.D. (1)
PMID 40576086, PMID 37853560, PMID 38323855, PMID 18423809, PMID 27007989, PMID 35239732, PMID 35810296, PMID 38781013, PMID 38972306, PMID 39910709